Effects of Evolocumab on the ApoA1 Remnant Ratio: A Pooled Analysis of Phase 3 Studies
Crossref DOI link: https://doi.org/10.1007/s40119-019-0133-6
Published Online: 2019-03-09
Published Print: 2019-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
May, Heidi T.
Muhlestein, Joseph B.
Ma, Yuhui
López, J. Antonio G.
Coll, Blai
Nelson, John
Funding for this research was provided by:
Amgen
Article History
Received: 11 January 2019
First Online: 9 March 2019